BREAKING NEWS: Anthos Therapeutics’ Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab, Demonstrated a 67% Greater Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding 
Compared to Rivaroxaban in Patients with Atrial Fibrillation

Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for CVM disease.

John Glasspool, a former leader of Novartis’ cardiovascular franchise with 30 years of experience in the biopharmaceutical industry, is CEO of Anthos Therapeutics. Mr. Glasspool served as Global Head of Novartis’ Cardiovascular and Metabolic Diseases franchise.


Dan Bloomfield, M.D

Chief Medical Officer

Debra Freedholm

SVP, Clinical Operations

Erika Dahl, Ph.D.

Program Manager

Mike Doremus

Head of Technical Operations

John Glasspool


Jonathan Freeman, Ph.D

Co-Founder and Chief Operating Officer

Gi Gi Galiano

Head, Project Management

Janeen Salter

Director of Clinical Operations

Bruce Hug, M.D., Ph.D

Vice President, Clinical Development

Alisha Lundholm, CPA, MSA

Corporate Controller

Drew Young

Chief Commercial Officer and Head of Patient Experience

David McIntyre B.EC., LL.B., CPA, MBA

Chief Financial Officer

Nik Mehta, Ph.D

Chief Technical and Regulatory Officer

Jessica Patrick Seabrook

Office Operations & Events Manager


Connie Cullen, PH.D

Principal Consultant

Yasser Khder, M.D, PH.D

Founder & Senior Consultant at MYRA Life Science Services


Scott Beardsley

Ari Brettman, M.D

Raymond Camahort

Mike Exton

Nicholas Galakatos, Ph.D

John Glasspool


Greg Norden

Paris Panayiotopoulos

Richard Pasternak, M.D

Peter Renehan, M.D.